文献速递新发突发、热带与寄生虫病

东南亚森林活动者的抗疟化学预防:一项开放标签、个体随机对照试验

Antimalarial chemoprophylaxis for forest goers in southeast Asia: an open-label, individually randomised controlled trial.
PubMed 文献 · Lancet Infect Dis · 2022-09-26

在柬埔寨开展开放标签个体随机对照试验,将1480名16-65岁森林过夜者随机分配接受蒿甲醚-苯芴醇化学预防或多种维生素。随访期间蒿甲醚-苯芴醇组疟原虫血症或临床疟疾风险为3%(19/713),显著低于多种维生素组的17%(123/714),绝对风险差15%(95%CI 12-18;p<0.0001)。

要点

  • 蒿甲醚-苯芴醇组疟疾复合终点风险3%,多种维生素组17%,绝对风险差15%(95%CI 12-18;p<0.0001)。
  • 间日疟风险蒿甲醚-苯芴醇组3% vs 多种维生素组16%,绝对风险差13%(95%CI 10-16;p<0.0001)。
  • 总体不良事件发生率蒿甲醚-苯芴醇组1.9% vs 多种维生素组1.1%(p<0.0001)。

核心结论

  • 蒿甲醚-苯芴醇化学预防可接受且耐受性良好,并大幅降低疟疾风险。
  • 作者认为,在森林工人等高危人群中开展疟疾化学预防可能成为加速大湄公河次区域消除疟疾的有价值工具。

研究设计与样本

  • 在柬埔寨开展的开放标签、个体随机对照试验,招募16-65岁在森林过夜者。
  • 参与者按1:1随机分配至蒿甲醚-苯芴醇化学预防组或多种维生素组,随机化采用计算机生成序列、区组大小为10并按村庄分层。
  • 蒿甲醚-苯芴醇方案为3天每日两次蒿甲醚-苯芴醇,随后在森林旅行期间每周一次相同日剂量,离开森林后继续4周(每剂四片,每片含蒿甲醚20 mg和苯芴醇120 mg)。
  • 主要结局为第1-28、29-56或57-84天内任何疟原虫种临床疟疾,或第28、56、84天PCR检测的亚临床感染,采用意向治疗人群的完整病例分析。
  • 共纳入1480人,蒿甲醚-苯芴醇组738人,多种维生素组742人;试验注册号NCT04041973,已完成。

主要发现

  • 随访期间蒿甲醚-苯芴醇组713人中有19人(3%,95%CI 2-4)出现疟原虫血症或临床疟疾,多种维生素组714人中有123人(17%,95%CI 15-20),绝对风险差15%(95%CI 12-18;p<0.0001)。
  • 间日疟感染人数蒿甲醚-苯芴醇组18人(3%,95%CI 2-4)vs 多种维生素组112人(16%,95%CI 13-19),绝对风险差13%(95%CI 10-16;p<0.0001)。
  • 恶性疟感染人数蒿甲醚-苯芴醇组2人(0.3%,95%CI 0.03-1.01)vs 多种维生素组12人(1.7%,95%CI 0.9-2.9),绝对风险差1.4%(95%CI 0.4-2.4;p=0.013)。
  • 随访期间共发生166例间日疟、14例恶性疟和5例其他或混合种感染。
  • 总体报告全程服药依从性蒿甲醚-苯芴醇组为97%(95%CI 96-98;1854个疗程中完成1797个),多种维生素组为98%(95%CI 97-98;1885个疗程中完成1842个)。

关键数值与推荐

  • 主要复合终点绝对风险差15%(95%CI 12-18;p<0.0001),蒿甲醚-苯芴醇组低于多种维生素组。
  • 间日疟绝对风险差13%(95%CI 10-16;p<0.0001),蒿甲醚-苯芴醇组低于多种维生素组。
  • 恶性疟绝对风险差1.4%(95%CI 0.4-2.4;p=0.013),蒿甲醚-苯芴醇组低于多种维生素组。
  • 全程服药依从性蒿甲醚-苯芴醇组97%(95%CI 96-98)vs 多种维生素组98%(95%CI 97-98)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malaria in the eastern Greater Mekong subregion has declined to historic lows. Countries in the Greater Mekong subregion are accelerating malaria elimination in the context of increasing antimalarial drug resistance. Infections are now increasingly concentrated in remote, forested foci. No intervention has yet shown satisfactory efficacy against forest-acquired malaria. The aim of this study was to assess the efficacy of malaria chemoprophylaxis among forest goers in Cambodia. METHODS: We conducted an open-label, individually randomised controlled trial in Cambodia, which recruited participants aged 16-65 years staying overnight in forests. Participants were randomly allocated 1:1 to antimalarial chemoprophylaxis, a 3-day course of twice-daily artemether-lumefantrine followed by the same daily dosing once a week while travelling in the forest and for a further 4 weeks after leaving the forest (four tablets per dose; 20 mg of artemether and 120 mg of lumefantrine per tablet), or a multivitamin with no antimalarial activity. Allocations were done according to a computer-generated randomisation schedule, and randomisation was in permuted blocks of size ten and stratified by village. Investigators and participants were not masked to drug allocation, but laboratory investigations were done without knowledge of allocation. The primary outcome was a composite endpoint of either clinical malaria with any Plasmodium species within 1-28, 29-56, or 57-84 days, or subclinical infection detected by PCR on days 28, 56, or 84 using complete-case analysis of the intention-to-treat population. Adherence to study drug was assessed primarily by self-reporting during follow-up visits. Adverse events were assessed in the intention-to-treat population as a secondary endpoint from self-reporting at any time, plus a physical examination and symptom questionnaire at follow-up. This trial is registered at ClinicalTrials.gov (NCT04041973) and is complete. FINDINGS: Between March 11 and Nov 20, 2020, 1480 individuals were enrolled, of whom 738 were randomly assigned to artemether-lumefantrine and 742 to the multivitamin. 713 participants in the artemether-lumefantrine group and 714 in the multivitamin group had a PCR result or confirmed clinical malaria by rapid diagnostic test during follow-up. During follow-up, 19 (3%, 95% CI 2-4) of 713 participants had parasitaemia or clinical malaria in the artemether-lumefantrine group and 123 (17%, 15-20) of 714 in the multivitamin group (absolute risk difference 15%, 95% CI 12-18; p<0·0001). During follow-up, there were 166 malaria episodes caused by Plasmodium vivax, 14 by Plasmodium falciparum, and five with other or mixed species infections. The numbers of participants with P vivax were 18 (3%, 95% CI 2-4) in the artemether-lumefantrine group versus 112 (16%, 13-19) in the multivitamin group (absolute risk difference 13%, 95% CI 10-16; p<0·0001). The numbers of participants with P falciparum were two (0·3%, 95% CI 0·03-1·01) in the artemether-lumefantrine group versus 12 (1·7%, 0·9-2·9) in the multivitamin group (absolute risk difference 1·4%, 95% CI 0·4-2·4; p=0·013). Overall reported adherence to the full course of medication was 97% (95% CI 96-98; 1797 completed courses out of 1854 courses started) in the artemether-lumefantrine group and 98% (97-98; 1842 completed courses in 1885 courses started) in the multivitamin group. Overall prevalence of adverse events was 1·9% (355 events in 18 806 doses) in the artemether-lumefantrine group and 1·1% (207 events in 19 132 doses) in the multivitamin group (p<0·0001). INTERPRETATION: Antimalarial chemoprophylaxis with artemether-lumefantrine was acceptable and well tolerated and substantially reduced the risk of malaria. Malaria chemoprophylaxis among high-risk groups such as forest workers could be a valuable tool for accelerating elimination in the Greater Mekong subregion. FUNDING: The Global Fund to Fight AIDS, Tuberculosis and Malaria; Wellcome Trust.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Tripura R, von Seidlein L, Sovannaroth S, et al. Antimalarial chemoprophylaxis for forest goers in southeast Asia: an open-label, individually randomised controlled trial. Lancet Infect Dis. 2022. PMID: 36174595. doi:10.1016/S1473-3099(22)00492-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。